Literature DB >> 25900734

HRCT of fibrosing lung disease.

Joseph Jacob1, David M Hansell1,2.   

Abstract

The use of high-resolution computed tomography (HRCT) has brought increased diagnostic discrimination to the evaluation of lung disease, particularly fibrosing lung diseases. Once the presence of a predominantly fibrosing lung disease has been established on evaluation of a HRCT, a stepwise approach is proposed that can refine the potential HRCT diagnoses from a list of over 100 different interstitial lung diseases to one of only five fibrosing lung diseases. Within the category of the fibrosing lung diseases, the recognition of idiopathic pulmonary fibrosis (IPF) is key. IPF is the most prevalent idiopathic interstitial pneumonia and has a mortality greater than any of the other diffuse lung diseases. Several diagnostic dilemmas are explored including challenges with the recent IPF diagnosis and management guidelines (2011), as well as with the 'difficult to characterize' fibrosing diseases such as smoking-related lung fibrosis, unclassifiable disease and acute exacerbations of fibrosing lung disease.
© 2015 Asian Pacific Society of Respirology.

Entities:  

Keywords:  computed tomography; fibrosis; idiopathic interstitial pneumonia; lung; prognosis

Mesh:

Year:  2015        PMID: 25900734     DOI: 10.1111/resp.12531

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

Review 1.  Errors in multidetector row computed tomography.

Authors:  M A Mazzei; L Volterrani
Journal:  Radiol Med       Date:  2015-06-25       Impact factor: 3.469

2.  Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Authors:  Ganesh Raghu; Athol U Wells; Andrew G Nicholson; Luca Richeldi; Kevin R Flaherty; Florence Le Maulf; Susanne Stowasser; Rozsa Schlenker-Herceg; David M Hansell
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

3.  The role of video-assisted thoracoscopic surgery in the diagnosis of interstitial lung disease.

Authors:  Keishi Sugino; Hajime Otsuka; Yusuke Matsumoto; Yasuhiko Nakamura; Keiko Matsumoto; Yoko Azuma; Takashi Makino; Akira Iyoda; Kazutoshi Shibuya; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 4.  Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Authors:  Fabrizio Luppi; Marco Sebastiani; Carlo Salvarani; Elisabeth Bendstrup; Andreina Manfredi
Journal:  Nat Rev Rheumatol       Date:  2021-12-07       Impact factor: 20.543

5.  Are interstitial lung abnormalities associated with COPD? A nested case-control study.

Authors:  Francesca Bozzetti; Ilaria Paladini; Enrico Rabaiotti; Alessandro Franceschini; Veronica Alfieri; Alfredo Chetta; Ernesto Crisafulli; Mario Silva; Ugo Pastorino; Nicola Sverzellati
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-26

Review 6.  Recent advances in managing idiopathic pulmonary fibrosis.

Authors:  Chiara Scelfo; Antonella Caminati; Sergio Harari
Journal:  F1000Res       Date:  2017-11-27

7.  Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist.

Authors:  Nicola Sverzellati; Anna Odone; Mario Silva; Roberta Polverosi; Carlo Florio; Luciano Cardinale; Giancarlo Cortese; Giancarlo Addonisio; Maurizio Zompatori; Giorgia Dalpiaz; Sara Piciucchi; Anna Rita Larici
Journal:  Radiol Med       Date:  2017-12-11       Impact factor: 3.469

Review 8.  [Artificial intelligence in lung imaging].

Authors:  F Prayer; S Röhrich; J Pan; J Hofmanninger; G Langs; H Prosch
Journal:  Radiologe       Date:  2020-01       Impact factor: 0.635

Review 9.  Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

Authors:  Amy Hajari Case; Peace Johnson
Journal:  BMJ Open Respir Res       Date:  2017-06-28

10.  Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers.

Authors:  Xiang-Yan Zhang; Rui Cao; Yi-Jia Guo; Yan-Hua Zhen; Jia-He Zheng; Le-Tian Huang; Shu-Ling Zhang; Wei Jing; Li Sun; Jian-Zhu Zhao; Cheng-Bo Han; Jie-Tao Ma
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.